Compare RVYL & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RVYL | NXL |
|---|---|---|
| Founded | 2007 | 2010 |
| Country | United States | United States |
| Employees | N/A | 7 |
| Industry | Professional Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3M | 8.3M |
| IPO Year | 2008 | N/A |
| Metric | RVYL | NXL |
|---|---|---|
| Price | $5.56 | $0.36 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 46.4K | ★ 101.7K |
| Earning Date | 05-19-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.34 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $55,998,000.00 | N/A |
| Revenue This Year | N/A | $120.99 |
| Revenue Next Year | $297.49 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.14 | $0.34 |
| 52 Week High | $8.55 | $2.31 |
| Indicator | RVYL | NXL |
|---|---|---|
| Relative Strength Index (RSI) | 49.95 | 37.77 |
| Support Level | $5.31 | N/A |
| Resistance Level | $6.15 | $0.46 |
| Average True Range (ATR) | 0.60 | 0.03 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 60.37 | 22.06 |
Ryvyl Inc is a technology company that develops, markets and sells blockchain-based payment solutions, which offers improvements to the payment solutions marketplace. Its focus is developing and monetizing disruptive blockchain-based applications, integrated within an end-to-end suite of financial products, capable of supporting a multitude of industries. Its proprietary, blockchain-based systems are designed to facilitate, record, and store a limitless volume of tokenized assets, representing cash or data, on a secured immutable blockchain-based ledger. It has two reportable segments North America and International. It generates the majority of its revenue from North America.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.